Barrington analyst Michael Petusky lowered his price target for Anika Therapeutics to $44 citing the likely absence of a previously expected $5M Monovisc milestone payment. The analyst, however, keeps an Outperform rating on the shares following the company’s Q4 results.
https://thefly.com/landingPageNews.php?id=2868747
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.